PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.
Kim I, Choi SH, Lee SY, Yoo SS, Park JE, Shin KC, Jang JG, Hong KS, Kwon YS, Park SH, Choi KJ, Jung CY, Kim MH, Kim SH, Seol HY, Kim J, Park JH, Kim TH, Eom JS, Ahn JH.
Kim I, et al. Among authors: choi kj.
Anticancer Res. 2024 Oct;44(10):4505-4516. doi: 10.21873/anticanres.17279.
Anticancer Res. 2024.
PMID: 39348962